9 terminated. 9 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Terminated 9 |
| Phase 2 | 2 | Terminated 2 |
Follow Liposarcoma: new trials by email Literature Review of Liposarcoma trials Research Report on Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer GSK3901961, Cyclophosphamide, Fludarabine - Neoplasms | Phase 1 | Terminated | Adaptimmune | 7 | 2021-03-09 | 2024-11-13 |
| Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma GSK3845097, Cyclophosphamide, Fludarabine - Neoplasms | Phase 1 | Terminated | Adaptimmune | 5 | 2020-12-21 | 2024-11-13 |
| Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors GSK3901961, GSK3845097, GSK4427296 - Neoplasms | Phase 1 | Terminated | Adaptimmune | 12 | 2020-12-21 | 2024-11-26 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors TP-1287 - Advanced Solid Tumors, Sarcoma | Phase 1 | Terminated | Sumitomo Pharma America, Inc. | 74 | 2018-12-26 | 2024-09-19 |
| NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine - Multiple Myeloma, Melanoma | Phase 1 | Terminated | University of Pennsylvania | 3 | 2018-09-05 | 2023-06-22 |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 35 | 2017-09-28 | 2022-04-29 |
| Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma nelfinavir mesylate, biopsy, laboratory biomarker analysis - Adult Liposarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | City of Hope Medical Center | 29 | 2006-03-01 | 2015-04-01 |
Liposarcoma, Myxoid (5) · Neoplasms (4) · Leiomyosarcoma (3) · Sarcoma (3) · Sarcoma, Synovial (3) · Melanoma (2) · Adenocarcinoma of Lung (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Mesothelioma, Malignant (1)
Neoplasms by Histologic Type (9) · Neoplasms, Adipose Tissue (9) · Neoplasms, Connective and Soft Tissue (9) · Sarcoma (6) · Neoplasms (5) · Neoplasms by Site (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Muscle Tissue (3) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2)
Cyclophosphamide (4) · fludarabine (4) · Biopsy (1) · Blotting, Western (1) · Gene Expression Profiling (1) · INCB039110 (1) · Immunoenzyme Techniques (1) · Nelfinavir (1) · Reverse Transcriptase Polymerase Chain Reaction (1) · Trabectedin (1) · avelumab (1) · baricitinib (1) · itacitinib (1)
Adaptimmune (3) · Fred Hutchinson Cancer Center (2) · City of Hope Medical Center (1) · Numab Therapeutics AG (1) · Sumitomo Pharma America, Inc. (1) · University of Pennsylvania (1)
United States (9) · Australia (3) · Canada (3) · Germany (3) · Netherlands (3) · Sweden (3)
Adaptimmune Patient Enquiries (3) · Edward Stadtmauer, MD (1) · Lee Cranmer (1) · Seth Pollack (1) · Warren Chow (1)
PMID 31215818, PMID 32029687, PMID 37794590
2019 (2), P30CA015704 (1)